Trial Profile

A phase III study to evaluate both double combinations buntanetap with GLP-1 agonist or PDE5 inhibitor

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 11 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Buntanetap (Primary) ; Dulaglutide (Primary) ; Sildenafil (Primary)
Indications Alzheimer's disease
Focus Registrational; Therapeutic Use

Most Recent Events

24 Nov 2025 According to Annovis Bio Inc, the study design will be presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place December 1-4, 2025 in San Diego, California.
13 Oct 2024 New trial record
03 Oct 2024 According to Annovis Bio media release, the company has secured intellectual property for innovative combination therapy involving buntanetap and Trulicity, which work together to enhance cognitive function.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com